Advancements in protein nanoparticle vaccine platforms to combat infectious disease.
Advancements in protein nanoparticle vaccine platforms to combat infectious disease.
复制标题
DOI：
10.1002/wnan.1681
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Wang SW
中科院分区：
文献类型：
--
作者：
Butkovich N;Li E;Ramirez A;Burkhardt AM;Wang SW
传染病是对全球人类健康的主要威胁，但预防性治疗选择可能有限，因为安全有效的疫苗仅适用于所有疾病的一小部分。值得注意的是，获得性免疫缺陷综合征（艾滋病）和2019年冠状病毒病（COVID-19）等毁灭性疾病目前没有疫苗疗法。常规的疫苗平台，如减毒活疫苗和全灭活疫苗，可能难以制造，可能引起严重的副作用，并且可能潜在地诱导严重感染。亚单位疫苗的安全性问题要少得多，因为它们不能引起基于疫苗的感染。蛋白质纳米颗粒（NPs）作为疫苗支架的适用性是有希望的，以防止感染性疾病，他们已经探索了一些病毒，细菌，真菌和寄生虫疾病。存在许多类型的蛋白质纳米粒子，包括自组装纳米粒子，噬菌体衍生的纳米粒子，植物衍生的纳米粒子，和人类病毒为基础的载体，这些特定的类别将在本次审查中涵盖。这些疫苗可以引发针对特定病原体的强烈体液和细胞免疫应答，以及在许多动物模型中提供针对感染的保护。此外，已发表的临床试验证明了应用这些NP疫苗平台的前景，除了目前临床上使用的多种病毒载体外，这些NP疫苗平台还包括噬菌体衍生的NP。对蛋白质NP疫苗平台的持续研究对于产生当前疫苗的更安全替代品、推进针对目前缺乏有效预防疗法的疾病的疫苗以及为针对新兴传染病的新疫苗的快速开发做好准备至关重要。各种蛋白质纳米颗粒（NP）已被用作支架以展示用于针对感染因子的疫苗接种的抗原。NP可以刺激体液免疫应答、细胞免疫应答或两者的组合。
Infectious diseases are a major threat to global human health, yet prophylactic treatment options can be limited, as safe and efficacious vaccines exist only for a fraction of all diseases. Notably, devastating diseases such as acquired immunodeficiency syndrome (AIDS) and coronavirus disease of 2019 (COVID-19) currently do not have vaccine therapies. Conventional vaccine platforms, such as live attenuated vaccines and whole inactivated vaccines, can be difficult to manufacture, may cause severe side effects, and can potentially induce severe infection. Subunit vaccines carry far fewer safety concerns due to their inability to cause vaccine-based infections. The applicability of protein nanoparticles (NPs) as vaccine scaffolds is promising to prevent infectious diseases, and they have been explored for a number of viral, bacterial, fungal, and parasitic diseases. Many types of protein NPs exist, including self-assembling NPs, bacteriophage-derived NPs, plant-derived NPs, and human virus-based vectors, and these particular categories will be covered in this review. These vaccines can elicit strong humoral and cellular immune responses against specific pathogens, as well as provide protection against infection in a number of animal models. Furthermore, published clinical trials demonstrate the promise of applying these NP vaccine platforms, which include bacteriophage-derived NPs, in addition to multiple viral vectors that are currently used in the clinic. The continued investigations of protein NP vaccine platforms are critical to generate safer alternatives to current vaccines, advance vaccines for diseases that currently lack effective prophylactic therapies, and prepare for the rapid development of new vaccines against emerging infectious diseases. Various protein nanoparticles (NPs) have been utilized as scaffolds to display antigens for vaccination against infectious agents. NPs can stimulate humoral immune responses, cellular immune responses, or a combination of both.
登录
查看更多内容
影响因子：
33.7
作者：
Agmon-Levin, Nancy;Paz, Ziv;Shoenfeld, Yehuda
通讯作者：
Shoenfeld, Yehuda
DOI：
10.1073/pnas.1011218107
发表时间：
2010-11-23
影响因子：
11.1
作者：
Bartual, Sergio G.;Otero, Jose M.;van Raaij, Mark J.
通讯作者：
van Raaij, Mark J.
影响因子：
--
作者：
Carter, Daniel C.;Wright, Brenda;Wilson, Ellen
通讯作者：
Wilson, Ellen
影响因子：
4.3
作者：
Bull, James J.;Nuismer, Scott L.;Antia, Rustom
通讯作者：
Antia, Rustom
影响因子：
4.6
作者：
Chen F;Jiang R;Wang Y;Zhu M;Zhang X;Dong S;Shi H;Wang L
通讯作者：
Wang L